Label-inconsistent use of sibutramine in spontaneous adverse drug reaction reports in Germany

International Journal of Clinical Pharmacology and Therapeutics

Volumn 46, Issue 7, 2008, Pages 375-381

  Seebeck, Jeorg ^a   Wulf, F ^a   Sachs, B ^a  

^a FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES   (Germany)

Author keywords

Dear doctor letter; Drug utilization; Obesity; Off label use; Prescription; Sibutramine

Indexed keywords

SIBUTRAMINE;

ADULT; ARTICLE; BLADDER DISEASE; BLOOD TOXICITY; BODY MASS; BREAST DISEASE; CARDIOTOXICITY; CLINICAL TRIAL; DATA ANALYSIS; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG INDICATION; DRUG INFORMATION; DRUG LABELING; DRUG SAFETY; EAR DISEASE; ENDOCRINE DISEASE; EYE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; HEPATOBILIARY DISEASE; HUMAN; IMMUNOPATHOLOGY; INFECTION; INFESTATION; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC DISORDER; NEOPLASM; NEPHROTOXICITY; NEUROTOXICITY; NUTRITIONAL DISORDER; OBESITY; RECOMMENDED DRUG DOSE; REPRODUCTIVE TOXICITY; SKIN TOXICITY; VASCULAR DISEASE;

EID: 47549084281     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP46375     Document Type: Article

References (14)

1. Anonymous. Eudralex; Volume 9A of the Rules Governing Medicinal Products in the European Union. Available at: http://ec.europa.eu/ enterprise/pharmaceuticals/eudralex/homev9.htm (accessed 28 January 2008).
2. Avenell A, Sattar N, Lean M. ABC of obesity. Management: Part I - Behaviour change, diet, activity. BMJ. 2006; 333: 740-743.
3. Dahlin A, Beermann B. Incorrect use of orlistat and sibutramine in clinical practice. Eur J Clin Pharm. 2007; 63: 205-209.
4. Eckel HR, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005; 365: 1415-1428.
5. Garcia Rodriguez LA, Perez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol. 1998; 45: 419-425.
6. Guo JJ, Curkendall S, Jones JK, Fife D, Goehring E, She DS. Impact of cisapride label changes on codispensing of contraindicated medications. Pharmacoepidemiol Drug Saf. 2003; 12: 295-301.
7. Haslam DW, James WPT. Obesity. Lancet. 2005; 366: 1197-1209.
8. Hauben M, Reich L. Communication of findings in pharmacovigilance: use of the term "signal" and the need for precision in its use. Eur J Clin Pharmacol. 2005; 61: 479-480.
9. Mazor KM, Andrade SE, Auger J, Fish L, Gurwitz JH. Communicating safety information to physicians: an examination of dear doctor letters. Pharmacoepidemiol Drug Saf. 2005; 14: 869-875.
10. Meyboom RHB. Causal or casual? The role of causality assessment in pharmacovigilance. Drug Safety. 1997; 17: 374-389.
11. Onyike CU, Crum RM, Lee HB, Lyketsos CG, Eaton WW. Is obesity associated with major depression? Results from the third National Health and Nutrition Examination Survey. Am J Epidemiol. 2003; 158: 1139-1147.
12. Smalley W, Shatin D, Wysowski DK, Gurwitz J, Andrade SE, Goodman M, Chan KA, Platt R, Schech SD, Ray WA. Contraindicated use of cisapride. JAMA. 2000; 284: 3036-3039.
13. The European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products. Opinion Following an Article 31 Referral. Sibutramine. Available at: http://www.emea.eu.int/ pdfs/human/referral/451402en.pdf (accessed 9 December 2006).
14. Weber JCP. Epidemiology of adverse drug reactions to nonsteroidal antiinflammatory drugs. In: Rainsford KD, Velo GP (eds.) Advances in inflammation research. Volume 6. New York: Raven Press; 1984. p. 1-7.